Insilico Medicine raises $60m in Series D round
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, has completed a $60 million Series D financing from a syndicate of global investors with expertise in investing in the biopharmaceutical and life sciences sectors.